{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:49:28Z","timestamp":1761630568132,"version":"3.33.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1136\/ard.2010.139824","type":"journal-article","created":{"date-parts":[[2010,12,6]],"date-time":"2010-12-06T01:24:25Z","timestamp":1291598665000},"page":"1343-1344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Successful clearance of hepatitis C virus with pegylated interferon \u03b1-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis"],"prefix":"10.1016","volume":"70","author":[{"given":"Ingmar","family":"Mederacke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Meyer-Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2010.139824_bib1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1136\/ard.2010.139824_bib2","first-page":"421","article-title":"Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis","volume":"35","author":"Cansu","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.139824_bib3","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","article-title":"Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"69","author":"Vassilopoulos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.139824_bib4","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.139824_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B","volume":"50","author":"European Association for the Study of the Liver","year":"2009","journal-title":"J Hepatol"},{"key":"10.1136\/ard.2010.139824_bib6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1136\/ard.2010.139824_bib7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1517\/14656561003637659","article-title":"Treatment of HBV\/HCV coinfection","volume":"11","author":"Potthoff","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1136\/ard.2010.139824_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1136\/ard.2010.139824_bib9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/art.21949","article-title":"Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C","volume":"54","author":"Niewold","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.139824_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2230.2009.03476.x","article-title":"Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection","volume":"35","author":"Behnam","year":"2010","journal-title":"Clin Exp Dermatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724100672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724100672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2010.139824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:28:56Z","timestamp":1737437336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724100672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0003496724100672"],"URL":"https:\/\/doi.org\/10.1136\/ard.2010.139824","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful clearance of hepatitis C virus with pegylated interferon \u03b1-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2010.139824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc. For permission to use (where not already granted under a licence) please go to http:\/\/group.bmj.com\/group\/rights-licensing\/permissions. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}